Asian Pain Academy

Chronic low back pain (CLBP) is one of the most common causes of disability worldwide and remains a major challenge for clinicians. While conventional imaging often focuses on discs, facet joints, and neural compression, growing evidence suggests that dysfunction of the lumbar multifidus muscle (LMM) plays a critical role in persistent spinal pain and instability. Musculoskeletal ultrasound (MSK-US) has emerged as a valuable imaging modality for evaluating multifidus morpholo

Chronic pain has traditionally been classified into two major categories: nociceptive pain and neuropathic pain. While this framework has guided clinicians for decades, a significant number of patients continue to experience persistent pain that does not fit neatly into either category. These individuals often have widespread pain, fatigue, sensory hypersensitivity, sleep disturbances, and emotional distress despite minimal tissue injury or clear nerve damage. To address this

Buttock pain is a common yet diagnostically challenging complaint encountered in pain clinics, spine practices, and rehabilitation settings. While sacroiliac joint dysfunction, lumbar radiculopathy, piriformis syndrome, and facetogenic pain are frequently considered, cluneal nerve entrapment remains an under-recognized cause of chronic buttock and low back pain. Failure to identify cluneal neuralgia can lead to prolonged suffering, unnecessary imaging, failed spine interventi

Pain Management Fellowship in India 2026 If you've been thinking about stepping into interventional pain medicine — or taking your existing skills to the next level — April 2026 might just be the turning point in your career. Asian Pain Academy (APA) is launching its next batch of Pain Management Fellowship programs on 8th April 2026 , and whether you're a fresh postgraduate looking for direction or a seasoned clinician wanting to add procedural skills, there's a program buil

Author: Dr. Debjyoti Dutta, Pain Physician Reviewed by: Dr. Chinmoy Roy, Pain Physician Introduction The year 2026 marks a pivotal moment in metabolic medicine in India . With the anticipated expiry of patent protection for semaglutide , the active molecule behind widely used anti-diabetic and anti-obesity medications, the Indian pharmaceutical landscape is poised for a major transformation. The emergence of Semaglutide Generics India 2026 is expected to significantly expan